Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with advanced solid tumors.

Condition or disease	Intervention/treatment	Phase
Advanced Solid Tumors	Drug: aldoxorubicin	Phase 1

Detailed Description:

An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin Administered as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	18 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Study Start Date :	October 2012
Actual Primary Completion Date :	December 2014
Actual Study Completion Date :	December 2014

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Aldoxorubicin; Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.	Drug: aldoxorubicin; Other Name: INNO-206

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Pharmacokinetics [ Time Frame: up to 3 months ]
   Blood samples will be obtained for pharmacokinetics. Standard pharmacokinetic parameters, including t1/2, Cmax, AUC, Vd and CL, will be determined.

Secondary Outcome Measures :

1. Safety [ Time Frame: up to 6 months ]

   All subjects who receive any amount of aldoxorubicin will be included in the safety analyses, which will include the following:

   1. The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the subject's physical examination, vital signs, and clinical laboratory results.
   2. Deaths and other SAEs will be tabulated.

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

1. Age ≥18 years, male or female.
2. Histologically or cytologically confirmed malignant solid tumor that has relapsed or is refractory to standard therapy.
3. Subjects who have received prior radiation therapy with stable central nervous system (CNS) metastasis with no progression of brain metastasis by CT/MRI scan in last 4 weeks.
4. Capable of providing informed consent and complying with trial procedures.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
6. Life expectancy >12 weeks.
7. Measurable or evaluable disease.
8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. [Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.].
9. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
10. Geographic accessibility to the site.

Exclusion Criteria:

1. Palliative surgery, chemotherapy, immunotherapy and/or radiation treatment less than 4 weeks prior to the Screening Visit.
2. Exposure to any investigational agent within 30 days of the Screening Visit.
3. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or 5 times the ULN in liver metastases, total bilirubin greater than 3 times the ULN, white blood cell (WBC) count <3500/mm3, absolute neutrophil (ANC) count < 2000/mm3, platelet concentration <100,000/mm3, hematocrit level <25% for females or <28% for males (transfusion is allowed during screening).
4. Clinically evident congestive heart failure (CHF) > class II of the New York Heart Association (NYHA) guidelines.
5. Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.
6. Recent history (within 6 months) or current signs of active coronary artery disease with or without angina pectoris.
7. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) <45% of predicted.
8. Known history of HIV infection.
9. Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals.
10. Major surgery within 4 weeks prior to treatment.
11. Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results.
12. Any condition that is unstable and could jeopardize the subject's participation in the study.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, California
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States, 90048

Sponsors and Collaborators

CytRx

Investigators

Study Director:	Dan Levitt, MD	CytRx Coorporation

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	CytRx
ClinicalTrials.gov Identifier:	NCT01706835 History of Changes
Other Study ID Numbers:	ALDOXORUBICIN-P1-PK-01
First Posted:	October 15, 2012
Last Update Posted:	December 17, 2014
Last Verified:	December 2014

Keywords provided by CytRx:

solid tumor; aldoxorubicin; phase 1; pharmacokinetic; INNO-206

Additional relevant MeSH terms:

Doxorubicin; Antibiotics, Antineoplastic; Antineoplastic Agents; Topoisomerase II Inhibitors	Topoisomerase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action